GB201417002D0 - Novel compound - Google Patents
Novel compoundInfo
- Publication number
- GB201417002D0 GB201417002D0 GBGB1417002.1A GB201417002A GB201417002D0 GB 201417002 D0 GB201417002 D0 GB 201417002D0 GB 201417002 A GB201417002 A GB 201417002A GB 201417002 D0 GB201417002 D0 GB 201417002D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- novel compound
- novel
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (40)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1417002.1A GB201417002D0 (en) | 2014-09-26 | 2014-09-26 | Novel compound |
| RS20181417A RS58000B1 (sr) | 2014-09-26 | 2015-09-22 | Derivati naftiridina kao antagonisti alfa v beta 6 integrina za lečenje npr. fibrotičnih bolesti |
| KR1020177007738A KR101998000B1 (ko) | 2014-09-26 | 2015-09-22 | 신규한 화합물 |
| PL15767475T PL3197892T3 (pl) | 2014-09-26 | 2015-09-22 | Pochodne naftyrydyny jako antagonisty integryny alfa v beta 6 do leczenia, na przykład, chorób zwłóknienowych |
| UAA201703900A UA119181C2 (uk) | 2014-09-26 | 2015-09-22 | СПОЛУКИ ПІРОЛІДИНУ ЯК АНТАГОНІСТИ ІНТЕГРИНУ ανβ6 |
| SG11201701183YA SG11201701183YA (en) | 2014-09-26 | 2015-09-22 | Novel compounds |
| PCT/EP2015/071776 WO2016046225A1 (en) | 2014-09-26 | 2015-09-22 | Novel compounds |
| US15/514,399 US9956209B2 (en) | 2014-09-26 | 2015-09-22 | Compounds αv β6 integrin antagonists |
| PE2017000380A PE20170502A1 (es) | 2014-09-26 | 2015-09-22 | ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6 |
| MA40580A MA40580B1 (fr) | 2014-09-26 | 2015-09-22 | Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques |
| CA2962315A CA2962315A1 (en) | 2014-09-26 | 2015-09-22 | Novel compounds |
| MX2017003948A MX2017003948A (es) | 2014-09-26 | 2015-09-22 | Nuevos compuestos. |
| UY0001036314A UY36314A (es) | 2014-09-26 | 2015-09-22 | NUEVOS COMPUESTOS ANTAGONISTAS DE INTEGRINA avß6. |
| CR20170112A CR20170112A (es) | 2014-09-26 | 2015-09-22 | NUEVOS COMPUESTOS ANTAGONISTAS DE INTEGRINA avß6 |
| BR112017006251A BR112017006251A2 (pt) | 2014-09-26 | 2015-09-22 | novos compostos |
| JOP/2015/0234A JO3413B1 (ar) | 2014-09-26 | 2015-09-22 | مشتقات نافثيريدين في صورة مضادات ألفا v بيتا 6 إنتيجرين لعلاج الأمراض الليفية e.g |
| DK15767475.5T DK3197892T3 (en) | 2014-09-26 | 2015-09-22 | Naphthyridine derivatives such as alpha V beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases |
| EA201790715A EA031481B1 (ru) | 2014-09-26 | 2015-09-22 | АНТАГОНИСТЫ ИНТЕГРИНА αβИ ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ФИБРОЗА |
| TW104131366A TW201629056A (zh) | 2014-09-26 | 2015-09-22 | 新穎化合物αｖβ整聯蛋白拮抗劑 |
| JP2017516387A JP6611799B2 (ja) | 2014-09-26 | 2015-09-22 | 新規化合物 |
| SI201530476T SI3197892T1 (sl) | 2014-09-26 | 2015-09-22 | Derivati naftiridina kot antagonisti alfa v beta 6 integrina za zdravljenje npr. fibrotičnih bolezni |
| CN201580050280.XA CN107074848B (zh) | 2014-09-26 | 2015-09-22 | 吡咯烷化合物 |
| AU2015320858A AU2015320858B2 (en) | 2014-09-26 | 2015-09-22 | Novel compounds |
| EP15767475.5A EP3197892B1 (en) | 2014-09-26 | 2015-09-22 | Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases |
| SM20180513T SMT201800513T1 (it) | 2014-09-26 | 2015-09-22 | Derivati di naftiridina come antagonisti dell'integrina alfa v beta 6 per il trattamento ad esempio di malattie fibrotiche |
| HRP20181796TT HRP20181796T1 (hr) | 2014-09-26 | 2015-09-22 | Derivati naftiridina kao antagonisti alfa v beta 6 integrina, namijenjeni liječenju, primjerice, fibrotičnih bolesti |
| ES15767475.5T ES2690748T3 (es) | 2014-09-26 | 2015-09-22 | Derivados de naftiridina como antagonistas de integrina alfa v beta 6 para el tratamiento de enfermedades fibróticas entre otras |
| PT15767475T PT3197892T (pt) | 2014-09-26 | 2015-09-22 | Derivados da naftiridina como antagonistas de integrina alfa v beta 6 para o tratamento de e.g. doenças fibróticas |
| EP18191644.6A EP3428167A1 (en) | 2014-09-26 | 2015-09-22 | Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of fibrotic diseases |
| HUE15767475A HUE041827T2 (hu) | 2014-09-26 | 2015-09-22 | Alfa V béta 6 integrin-antagonista hatású naftiridin-származékok, például fibrotikus betegségek kezelésére |
| ARP150103047A AR101994A1 (es) | 2014-09-26 | 2015-09-22 | COMPUESTOS DE PIRROLIDINA ANTAGONISTAS DE INTEGRINA avb6 |
| LTEP15767475.5T LT3197892T (lt) | 2014-09-26 | 2015-09-22 | Naftiridino dariniai, kaip alfa v beta 6 integrino antagonistai, skirti fibrozinių ligų gydymui |
| IL250592A IL250592A0 (en) | 2014-09-26 | 2017-02-14 | new compounds |
| PH12017500361A PH12017500361A1 (en) | 2014-09-26 | 2017-02-28 | Novel compounds |
| CONC2017/0002714A CO2017002714A2 (es) | 2014-09-26 | 2017-03-22 | Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo |
| DO2017000081A DOP2017000081A (es) | 2014-09-26 | 2017-03-23 | NUEVOS COMPUESTOS ANTAGONISTAS DE INTEGRINA aVß6 |
| CL2017000705A CL2017000705A1 (es) | 2014-09-26 | 2017-03-23 | Nuevos compuestos |
| US15/922,674 US10342783B2 (en) | 2014-09-26 | 2018-03-15 | Compounds αvβ6 integrin antagonists |
| CY181101259T CY1121071T1 (el) | 2014-09-26 | 2018-11-27 | Παραγωγα ναφθυριδινης ως ανταγωνιστες ιντεγκρινης αλφα v βητα 6 για τη θεραπεια π.χ. ινωτικων νοσων |
| US16/423,455 US20190275016A1 (en) | 2014-09-26 | 2019-05-28 | NOVEL COMPOUNDS avB6 INTEGRIN ANTAGONISTS. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1417002.1A GB201417002D0 (en) | 2014-09-26 | 2014-09-26 | Novel compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201417002D0 true GB201417002D0 (en) | 2014-11-12 |
Family
ID=51901158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1417002.1A Ceased GB201417002D0 (en) | 2014-09-26 | 2014-09-26 | Novel compound |
Country Status (37)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201604589D0 (en) * | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604680D0 (en) * | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| PT3538525T (pt) | 2016-11-08 | 2022-08-16 | Bristol Myers Squibb Co | Ácidos propiónicos 3-substituídos por inibidores de alfa v integrina |
| CN110167934B (zh) | 2016-11-08 | 2022-06-10 | 百时美施贵宝公司 | 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物 |
| EP3538528B1 (en) | 2016-11-08 | 2020-12-23 | Bristol-Myers Squibb Company | Pyrrole amides as alpha v integrin inhibitors |
| EA201991123A1 (ru) | 2016-11-08 | 2019-11-29 | ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV | |
| AU2017359028A1 (en) | 2016-11-08 | 2019-06-20 | Bristol-Myers Squibb Company | Azole amides and amines as alpha V integrin inhibitors |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| EP4159727B1 (en) | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| US11332498B2 (en) | 2017-03-17 | 2022-05-17 | Technische Universitat Munchen | Ligands for integrin αVβ8, synthesis and uses thereof |
| JP7291696B2 (ja) | 2017-11-07 | 2023-06-15 | ブリストル－マイヤーズ スクイブ カンパニー | アルファｖインテグリン阻害剤としてのピロロピラジン誘導体 |
| CN108208177A (zh) * | 2017-11-28 | 2018-06-29 | 上海交通大学医学院附属新华医院 | 含丁酸类化合物的组合物及其应用 |
| WO2020047208A1 (en) * | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| PT3844162T (pt) * | 2018-08-29 | 2025-03-28 | Morphic Therapeutic Inc | Inibidores da integrina alfa v beta6 |
| AU2019327475B2 (en) | 2018-08-29 | 2025-06-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| EP3843728B1 (en) * | 2018-08-29 | 2025-04-30 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| JP2022512648A (ja) * | 2018-10-09 | 2022-02-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 心筋線維化の処置のためのαＶ－インテグリン（ＣＤ５１）阻害剤の使用 |
| US20240165195A1 (en) * | 2018-10-09 | 2024-05-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis |
| US11034710B2 (en) * | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK9192000A3 (en) | 1997-12-17 | 2001-03-12 | Merck & Co Inc | Integrin receptor antagonists |
| EP1047425A4 (en) | 1997-12-17 | 2009-04-22 | Merck & Co Inc | INTEGRIN RECEPTOR ANTAGONISTS |
| DE60035779T2 (de) | 1999-06-02 | 2008-04-30 | Merck & Co., Inc. | Alpha v integrin-rezeptor antagonisten |
| EP1194151A4 (en) | 1999-06-23 | 2003-01-15 | Merck & Co Inc | ANTAGONISTS OF THE INTEGRIN RECEPTORS |
| EP1229910A4 (en) * | 1999-10-04 | 2003-10-01 | Merck & Co Inc | integrin |
| YU32502A (sh) | 1999-11-08 | 2004-12-31 | Merck & Co.Inc. | Postupak i intermedijeri za proizvodnju imidazolidinonskih antagonista alfa v integrina |
| US6921767B2 (en) | 2000-06-15 | 2005-07-26 | Pharmacia Corporation | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives |
| JP2004511434A (ja) * | 2000-06-15 | 2004-04-15 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸 |
| AU7793501A (en) | 2000-07-26 | 2002-02-05 | Merck & Co Inc | Alpha v integrin receptor antagonists |
| AU2001290772A1 (en) | 2000-09-14 | 2002-03-26 | Merck And Co., Inc. | Alpha v integrin receptor antagonists |
| AU2002246757B2 (en) | 2001-01-03 | 2006-02-02 | Merck & Co., Inc. | Methods and compositions for treating periodontal disease |
| DE10112771A1 (de) | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| AR037517A1 (es) | 2001-11-05 | 2004-11-17 | Novartis Ag | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria |
| MY147019A (en) | 2002-03-13 | 2012-10-15 | Biogen Idec Inc | Anti-alpha v beta 6 antibodies |
| US20040224986A1 (en) * | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| BR0317600A (pt) | 2002-12-20 | 2005-11-29 | Pharmacia Corp | ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina |
| US6932865B2 (en) | 2003-04-11 | 2005-08-23 | Lockheed Martin Corporation | System and method of making single-crystal structures through free-form fabrication techniques |
| MX2009010050A (es) | 2007-03-23 | 2009-10-12 | Amgen Inc | Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k). |
| US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| JP2011500823A (ja) | 2007-10-22 | 2011-01-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体 |
| WO2011111880A1 (ko) | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| AU2014324426A1 (en) | 2013-09-30 | 2016-04-21 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| EP3925959A1 (en) | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
| AU2016228852A1 (en) | 2015-03-10 | 2017-10-19 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| GB201604589D0 (en) | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
-
2014
- 2014-09-26 GB GBGB1417002.1A patent/GB201417002D0/en not_active Ceased
-
2015
- 2015-09-22 SG SG11201701183YA patent/SG11201701183YA/en unknown
- 2015-09-22 CA CA2962315A patent/CA2962315A1/en not_active Abandoned
- 2015-09-22 MX MX2017003948A patent/MX2017003948A/es unknown
- 2015-09-22 KR KR1020177007738A patent/KR101998000B1/ko not_active Expired - Fee Related
- 2015-09-22 WO PCT/EP2015/071776 patent/WO2016046225A1/en not_active Ceased
- 2015-09-22 TW TW104131366A patent/TW201629056A/zh unknown
- 2015-09-22 SI SI201530476T patent/SI3197892T1/sl unknown
- 2015-09-22 UA UAA201703900A patent/UA119181C2/uk unknown
- 2015-09-22 ES ES15767475.5T patent/ES2690748T3/es active Active
- 2015-09-22 BR BR112017006251A patent/BR112017006251A2/pt not_active Application Discontinuation
- 2015-09-22 EP EP18191644.6A patent/EP3428167A1/en not_active Withdrawn
- 2015-09-22 HU HUE15767475A patent/HUE041827T2/hu unknown
- 2015-09-22 UY UY0001036314A patent/UY36314A/es not_active Application Discontinuation
- 2015-09-22 DK DK15767475.5T patent/DK3197892T3/en active
- 2015-09-22 PT PT15767475T patent/PT3197892T/pt unknown
- 2015-09-22 CR CR20170112A patent/CR20170112A/es unknown
- 2015-09-22 LT LTEP15767475.5T patent/LT3197892T/lt unknown
- 2015-09-22 AU AU2015320858A patent/AU2015320858B2/en not_active Ceased
- 2015-09-22 EP EP15767475.5A patent/EP3197892B1/en active Active
- 2015-09-22 HR HRP20181796TT patent/HRP20181796T1/hr unknown
- 2015-09-22 US US15/514,399 patent/US9956209B2/en not_active Expired - Fee Related
- 2015-09-22 PE PE2017000380A patent/PE20170502A1/es unknown
- 2015-09-22 SM SM20180513T patent/SMT201800513T1/it unknown
- 2015-09-22 RS RS20181417A patent/RS58000B1/sr unknown
- 2015-09-22 MA MA40580A patent/MA40580B1/fr unknown
- 2015-09-22 JO JOP/2015/0234A patent/JO3413B1/ar active
- 2015-09-22 JP JP2017516387A patent/JP6611799B2/ja not_active Expired - Fee Related
- 2015-09-22 EA EA201790715A patent/EA031481B1/ru not_active IP Right Cessation
- 2015-09-22 AR ARP150103047A patent/AR101994A1/es unknown
- 2015-09-22 CN CN201580050280.XA patent/CN107074848B/zh not_active Expired - Fee Related
- 2015-09-22 PL PL15767475T patent/PL3197892T3/pl unknown
-
2017
- 2017-02-14 IL IL250592A patent/IL250592A0/en unknown
- 2017-02-28 PH PH12017500361A patent/PH12017500361A1/en unknown
- 2017-03-22 CO CONC2017/0002714A patent/CO2017002714A2/es unknown
- 2017-03-23 CL CL2017000705A patent/CL2017000705A1/es unknown
- 2017-03-23 DO DO2017000081A patent/DOP2017000081A/es unknown
-
2018
- 2018-03-15 US US15/922,674 patent/US10342783B2/en not_active Expired - Fee Related
- 2018-11-27 CY CY181101259T patent/CY1121071T1/el unknown
-
2019
- 2019-05-28 US US16/423,455 patent/US20190275016A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250345A0 (en) | new compounds | |
| IL250592A0 (en) | new compounds | |
| IL248991A0 (en) | Converted dihydroisoquinolinone compounds | |
| PT3204377T (pt) | Método e dispositivo para transferir matrizes poliméricas para máquinas de moldagem e aplicação | |
| GB201417011D0 (en) | Novel compounds | |
| GB201417094D0 (en) | Novel compounds | |
| GB201417018D0 (en) | Novel compounds | |
| GB201405991D0 (en) | Novel compounds | |
| SG11201606693SA (en) | Novel compounds | |
| GB201411236D0 (en) | Novel compounds | |
| GB201411239D0 (en) | Novel compounds | |
| GB201404002D0 (en) | Novel compounds | |
| GB201413695D0 (en) | Compound | |
| GB201412238D0 (en) | Compound | |
| IL248983A0 (en) | new compounds | |
| GB201407694D0 (en) | Compound | |
| GB201419102D0 (en) | Novel compounds | |
| GB201407506D0 (en) | Novel compound | |
| GB201407693D0 (en) | Compound | |
| GB201418709D0 (en) | Compound | |
| PL3154977T3 (pl) | Nowe związki | |
| GB201405361D0 (en) | Compounds | |
| ZA201605726B (en) | Novel compounds | |
| GB201416988D0 (en) | Novel compound | |
| GB201413698D0 (en) | Compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |